Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.54 USD | -1.40% | +4.46% | +15.44% |
May. 09 | Transcript : Phathom Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.44% | 626M | C- | ||
+33.63% | 50.85B | B- | ||
-0.09% | 42.82B | B | ||
+49.62% | 42.03B | A | ||
-4.96% | 29.55B | C | ||
+11.18% | 26.11B | B- | ||
-21.95% | 19.13B | B | ||
+8.61% | 13.05B | B+ | ||
+28.31% | 12.16B | C+ | ||
+24.73% | 12.08B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PHAT Stock
- Ratings Phathom Pharmaceuticals, Inc.